Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Medivation Prostate Therapeutics LLC has 1 pending office action, 1 distinct examiner, and 1 distinct art unit currently active in the Biotechnology & Pharmaceuticals technology area. This concentration centralizes the prosecution effort for the company's current filings. The work being contained within this specific art unit indicates a technical review process within a specific division of the patent office. Practitioners should note that such a focused arrangement allows for a direct line of communication between the applicant and the USPTO.
The busiest examiner for this portfolio is AZPURU, CARLOS A, who is managing 1 pending action. Because this represents the entirety of the company's active prosecution, the outcome of the current cycle depends on the interaction with this examiner. The presence of only 1 distinct art unit and 1 distinct examiner limits the administrative task of tracking patent office communications. This profile is characteristic of a company with a specific intellectual property focus in the pharmaceutical sector. With the pending office action, the applicant can dedicate resources to the requirements of the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AZPURU, CARLOS A | 1 | 83.8% | +10.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18931464 | Formulations of Enzalutamide | AZPURU, CARLOS A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18931464 | Formulations of Enzalutamide | AZPURU, CARLOS A | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18931464 | Formulations of Enzalutamide | AZPURU, CARLOS A | 1617 | §102 | Non-Final OA | — | Pending | Oct 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedivation Prostate Therapeutics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Carlos A Azpuru has the most, with 1 of Medivation Prostate Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
